#USA #New York #Class Action #Pomerantz LLP #ADMA Biologics

Pomerantz Law Firm's Investor Alert for ADMA Biologics

Pomerantz LLP has recently made headlines by announcing a class action lawsuit against ADMA Biologics, Inc., a company listed on NASDAQ under the ticker symbol ADMA. This legal action arises from allegations that the company, as well as certain officers and/or directors, may have engaged in securities fraud or other unlawful practices that could have significantly impacted investors' decisions and financial outcomes.

The firm is particularly urging investors who have suffered losses related to their investments in ADMA Biologics to reach out to them. Those affected are advised to contact Danielle Peyton at Pomerantz, using the provided email or phone number. It is crucial for interested parties to provide essential information, such as their mailing address, telephone number, and details about the number of shares they purchased.

The crux of the class action lawsuit revolves around the claims that ADMA's reported financial growth may not be as robust as portrayed to investors. Reports from financial analysts, including one from Culper Research published on March 24, 2026, alleged that the growth figures reported were inflated due to improper sales practices, likened to a scheme of channel stuffing. In contrast to the company’s reported growth of 20% for the year 2025, it was estimated that, without such practices, ADMA’s revenue would have shown a decline of 3%.

Following these revelations, ADMA’s stock faced a drastic drop of $2.26, or approximately 16.63%, falling to a closing price of $11.33 per share the same day. The negative sentiment surrounding the company's management response intensified when Cantor Fitzgerald downgraded the stock just days later, expressing disappointment with the company’s lack of specific and actionable feedback to address the claims made in the Culper report. The aftermath of this downgrade reflected another significant decline in share price, which plummeted $1.34, or 13.91%, bringing the share price down to $8.29.

Investors who acquired ADMA securities during the designated class period must act quickly, as the deadline to seek appointment as Lead Plaintiff is looming on August 10, 2026. A copy of the filed complaint can be readily accessed via the firm’s website, providing additional context and details regarding the allegations and the legal process.

Pomerantz LLP stands out as one of the leading firms in corporate securities and antitrust class litigation, a legacy born from the vision of its founder, Abraham L. Pomerantz, known widely as a pioneer in this field. The firm has built an impressive track record of recovering substantial damages for victims of corporate misconduct, securities fraud, and other breaches of fiduciary duty. With over 85 years of fighting for investors’ rights, Pomerantz continues to uphold its mission to hold companies accountable for their actions.

In a climate where market transparency and corporate accountability are paramount, this class action lawsuit against ADMA Biologics highlights the importance of investor awareness and the need for diligent oversight when it comes to public companies. Investors are encouraged to stay informed about the proceedings and consider their options before the impending deadlines pass.

For more information, potential class members can visit Pomerantz Law Firm's website or contact the firm directly. It's crucial that affected investors take decisive action to protect their rights and interests in this matter.